PLTU·GraniteShares 2x Long PLTR Daily ETF

The ETF PLTU has seen a sharp institutional shift today as Leeward Financial Partners LLC trimmed its Palantir (PLTR) position by 74.9 % in the second quarter, leaving only a modest $609 k stake; this move signals a bearish stance amid broader rebalancing and raises questions about PLTR’s valuation ahead of its next earnings release. The cut comes as Palantir’s stock sits just above a key technical buy zone, suggesting short‑term bullish momentum but also hinting that resistance levels could temper gains if the breakout fails to hold. Meanwhile, Palantir’s latest quarterly report showed a 149 % jump in U.S. commercial revenue and a GAAP net income of $1.06 B, yet analysts remain split on upside, with consensus pricing a modest 9 % rise versus a 21 % target in independent models. The company’s 93 % revenue growth to $1.94 B and 47 % operating margin reinforce its premium valuation, but the 155 % Rule‑of‑40 score also underscores the need for sustained high growth to justify a 60× sales multiple. Across the ETF’s holdings, this earnings strength is counterbalanced by emerging competition: a £140 M merger between Arcturis Data and Akrivia Health is poised to challenge Palantir’s NHS contracts, potentially diverting revenue and pressuring pricing. The merger’s regulatory approval timeline and subsequent contract wins will be a key driver for PLTU’s exposure to the UK data‑analytics niche. In addition, the split institutional sentiment—Leeward’s sell versus Prospect Hill and ABN AMRO’s buy—highlights a broader debate over Palantir’s valuation and growth prospects. Over the next 1–10 trading days, traders should watch for confirmation of the technical breakout, any reversal signals, and the first earnings guidance from Palantir, while also monitoring the merger’s progress and any new NHS contract awards that could shift the competitive landscape.